Our Pipeline
Building a pipeline for advanced therapy medicines
We have a pipeline consisting of programs at different stages of development, within three platforms - cellular, extracellular vesicle therapy, and gene engineering
We target quantifiable medical benefits in multiple inflammatory/ NLRP3 therapeutic areas
PLATFORM
PROGRAM
INDICATIONS
PROOF-OF-CONCEPT
PRE-CLINICAL
IND-ENABLING
CLINICAL
KELI-101
KELI-102
KELI-103
KELI-104
KELI-105
Post-ischaemic acute kidney injury
Moderate to severe acute respiratory distress syndrome
Neutrophilic dermatosis
Cardiorenal syndrome
KELI-100
KELI-200
KELI-201
Extracellular vesicles (undisclosed indication)
KELI-300
KELI-301
Gene-engineering (undisclosed indication)
Symptomatic joint osteoarthritis
PROOF-OF-CONCEPT
PRE-CLINICAL
IND-ENABLING
CLINICAL
KELI-100 Platform
Symptomatic joint osteoarthritis
Post-ischaemic acute kidney injury
Moderate to severe acute respiratory distress syndrome
Neutrophilic dermatosis
Cardiorenal syndrome
KELI-200 Platform
PROOF-OF-CONCEPT
PRE-CLINICAL
IND-ENABLING
CLINICAL
Undisclosed indication (extracellular vesicles)
KELI-300 Platform
PROOF-OF-CONCEPT
PRE-CLINICAL
IND-ENABLING
CLINICAL
Undisclosed indication (gene-engineering)
KELI-101
KELI-102
KELI-103
KELI-104
KELI-105
KELI-201
KELI-301